Amring Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for AMRING PHARMS, and what generic alternatives to AMRING PHARMS drugs are available?
AMRING PHARMS has fourteen approved drugs.
There are eight US patents protecting AMRING PHARMS drugs.
There are eight patent family members on AMRING PHARMS drugs in two countries and thirty-one supplementary protection certificates in ten countries.
Drugs and US Patents for Amring Pharms
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Amring Pharms | LYSTEDA | tranexamic acid | TABLET;ORAL | 022430-001 | Nov 13, 2009 | AB | RX | Yes | Yes | 8,273,795 | ⤷ Try a Trial | ⤷ Try a Trial | |||
Amring Pharms | LATANOPROST | latanoprost | SOLUTION/DROPS;OPHTHALMIC | 200925-001 | Mar 22, 2011 | AT | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Amring Pharms | LAMOTRIGINE | lamotrigine | TABLET, ORALLY DISINTEGRATING;ORAL | 214124-002 | Feb 3, 2022 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for AMRING PHARMS drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 650 mg | ➤ Subscribe | 2011-05-24 |
International Patents for Amring Pharms Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Japan | 5205053 | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2006023000 | ⤷ Try a Trial |
Japan | 2014193878 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Amring Pharms Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
3461484 | 21C1024 | France | ⤷ Try a Trial | PRODUCT NAME: ASSOCIATION DE NETARSUDIL OU L'UN DE SES SELS ET DE LATANOPROST; REGISTRATION NO/DATE: EU/1/20/1502 20210108 |
1586316 | 2011C/027 | Belgium | ⤷ Try a Trial | PRODUCT NAME: BROMFENAC; AUTHORISATION NUMBER AND DATE: EU/1/11/692/001 20110523 |
0364417 | C970039 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: [1R-[1 ALPHA (Z),2 BETA(R*),3 ALPHA,5ALPHA]]-7-[3,5-DIHYDROXY-2-(3-HYDROXY-5- FENYLPENTYL)CYCLOPENTYL]-5-HEPTEENZUUR, DESGEWENST IN DE VORM VAN EEN ZOUT OF EEN ESTER, IN HET BIJZONDER LATANOPROSTUM; NAT. REGISTRATION NO/DATE: RVG 21304 19970610; FIRST REGISTRATION: SE 12716 19960718 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.